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Abstract 
Background: The IFCC Committee for Standardization of Thyroid Function Tests intended 
to standardize free thyroxine (FT4) immunoassays. We developed a Système International 
d’Unités traceable conventional reference measurement procedure (RMP) based on 
equilibrium dialysis and mass spectrometry. We describe here the latest studies intended to 
recalibrate against the RMP and supply a proof-of-concept, which should allow continued 
standardization efforts.  
Methods: We used the RMP to target the standardization and reference interval (RI) panels, 
which were also measured by 13 manufacturers. We validated the suitability of the 
recalibrated results to meet specifications for bias (3.3%) and total error (8.0%) determined 
from biological variation. However, since these specifications were very stringent, we 
expanded them to 10% and 13%, respectively. The results for the RI panel were reported as 
if the assays were recalibrated. We estimated all but one RI using parametric statistical 
procedures and hypothesized that the RI determined by the RMP was suitable for use by the 
recalibrated assays. 
Results: Twelve of 13 recalibrated assays had a bias meeting the 10% specification with 
95% confidence; for 7 assays this applied even for the 3.3% specification. Only 1 assay met 
the 13% total error specification. Recalibration reduced the CV of the assay means for the 
standardization panel from 13% to 5%. The proof-of-concept study confirmed our hypothesis 
regarding the RI but within constraints. 
Conclusion: Recalibration to the RMP significantly reduced the FT4 immunoassay bias, so 
that the RI determined by the RMP was suitable for common use within a margin of 12.5%. 
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Introduction  
The diagnosis of metabolic thyroid disorders and/or monitoring of treatment is based on 
laboratory testing of serum thyroid-stimulating hormone (TSH) and free thyroxine (FT4). 
Provided the hypothalamic-pituitary-thyroid axis is intact, a first line TSH result may suggest 
a number of thyroid disorders that could be clarified by follow-up measurement of FT4; 
however, immediate combined measurement is indicated for the differential diagnosis 
between mild (subclinical) primary hyperthyroidism, and secondary (central) hypothyroidism. 
Furthermore combined measurement is warranted during the first days/weeks of the follow-
up of patients with severe thyroid dysfunction, where TSH has not yet return to a euthyroid 
baseline concentration and thus not representative of the actual thyroid functional status 
(e.g., in patients with autoimmune Graves' disease and high titers of TSH receptor antibodies 
or with increased human chorionic gonadotropin concentrations). On the other hand, FT4 is 
the primary test for the titration of levothyroxine replacement in patients with central 
hypothyroidism and/or with high risk differentiated thyroid cancer with need for a suppressed 
TSH (1-5). For maximum effectiveness, current FT4 immunoassays would benefit from 
improved clinical and analytical consistency (6, 7). Additionally, the issue of substantial inter-
method variability needs to be resolved for improved everyday patient care because it 
requires interpretation of laboratory results against assay-specific reference intervals (RIs) 
and prevents incorporation of common decision levels in evidence-based practice guidelines 
(7, 8). Therefore, the IFCC Committee for Standardization of Thyroid Function Testing was 
commissioned to standardize FT4 measurements globally (9). The committee’s efforts have 
been endorsed by the clinical community, which also called for general standardization of 
hormonal assays in the 21st century (10).  
The committee conducted the standardization activities of FT4 measurements in 
partnership with the same in vitro diagnostic (IVD) manufacturers (with one exception) that 
had been involved in the TSH harmonization (11). The committee pursued a process similar 
to that used for the TSH assays, except for FT4 for they developed and used a reference 
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measurement system with traceability to the Système International d’Unités (SI) (12, 13). The 
committee defined the measurand and developed/validated a conventional reference 
measurement procedure (RMP) based on equilibrium dialysis combined with isotope dilution-
liquid chromatography-tandem mass spectrometry (ED-ID-LC-MS/MS) (14-16), and 
undertook several method comparisons (MCs) with single-donation and commutable serum 
samples (Phase I to III studies) according to the “step-up” approach (8, 17-19). Each of the 
studies had a different focus, including documentation of the assays’ intrinsic quality and 
demonstration of the feasibility of standardization of assay results by recalibrating the 
immunoassays to the RMP.  
Here we report, on behalf of the Committee for Standardization of Thyroid Function 
Testing, our latest activities in the standardization process. We performed a Phase IV MC 
study between 13 immunoassays and the RMP. There were two objectives. First, to establish 
calibration traceability of the participating assays to the SI-traceable RMP. Second, to 
validate the efficiency of the process to eliminate the assay-specific biases. Subsequently, 
we conducted a RI study with a new panel of samples to test the proof-of-concept that, after 
standardization, immunoassays might accord sufficiently with the RMP to enable adoption of 
a common RI for diagnosis and follow-up of patients with thyroid dysfunction. 
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Material and methods  
Panels of clinical samples and value assignment 
We collected standardization and RI panels. The standardization panel comprised 91 
clinically relevant samples and was intended to facilitate the calibration 
adjustment/readjustment by the manufacturers to the IFCC RMP. The aim of the RI panel 
was to let manufacturers evaluate their recalibration, for which we used 120 samples 
donated by apparently healthy American volunteers. The sources, eligibility and exclusion 
criteria, conditions for sampling, processing and storage were those described before for the 
TSH harmonization effort (11). Approval from a Bioethic Committee and informed consent 
from the patients was obtained along with a short description of the clinical background of the 
donating patients. The target values (mean of minimum 3 independent measurements) were 
assigned with the IFCC conventional RMP performed at the reference laboratory of Ghent 
University. Both are listed in the Database of the Joint Committee for Traceability in 
Laboratory Medicine (20).  
 
Study participants and measurement protocol  
Thirteen IVD manufacturers participated in the current studies, each with one assay (coding 
and further details on the platforms/assays in Table 1). We requested that the IVD 
manufacturers perform all measurements according to a proposed randomized sequence, in 
singleton on each of two days, and include their master calibrators for measurement in 
parallel with the panel samples. The individual results were reported. The samples for the RI 
study were measured in order of their ascending ID number, in singleton and within a single 
run. Of note, that the organization and interpretation of internal QC was left to the discretion 
of each manufacturer.  
 
Recalibration of immunoassays  
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After submitting the results for measurement of the standardization panel with the assays’ 
current calibrators, the IVD manufacturers received from us a preliminary validation report, 
comprising the target concentrations determined by the RMP. These were intended for use in 
value reassignment of the master calibrators. The manufacturers were entitled to use their in-
house mathematical procedure to determine the relationship of their assay results to those 
from the RMP (11). After the readjustment of the master calibrators, the manufacturers 
recalculated and reported back the results for the standardization panel as if they were 
obtained with the recalibrated assays. The results for measurement of the RI panel were 
similarly reported after transformation to the revised calibration.  
 
Data treatment  
For consolidation of the MC study data we used Microsoft EXCEL® 2010. We concentrated 
on demonstrating and validating the efficiency of the recalibration process. We calculated for 
each assay i) the pre- and post-recalibration median deviation (%) to the RMP in several FT4 
concentration intervals, ii) the mean deviation (%) or bias (and one-sided 95% confidence 
interval (CI)) after recalibration, iii) the total error (TE, %) from the first replicate after 
recalibration, and iv) the differences between the replicates (in % of the mean). We also 
compared the pre- and post-recalibration CVs (%) of the assay means. 
We used CBstat (version 5.1) for statistical evaluation of the data from the RI study. 
This software evaluated normality of data distributions by the Anderson-Darling (A-D) test 
(P0.05), did outlier testing on the basis of power-transformed values (limit 4SD), and 
supplied parametric (direct on the original data and/or after transformation) as well as non-
parametric procedures to estimate the RI characteristics. For the normally distributed 
datasets we used the direct parametric procedure [RI estimated as mean+/-1.96(1/(1-1/(4(n-
1)))) * SD]. For those datasets for which normality did not apply, we selected the procedure 
after a sequence of investigations, i.e., in addition to the detection of statistical outliers, we 
did a visual screening for aberrant differences (%) to the RMP targets. If after omission of the 
detected values the A-D test allowed acceptance of the hypothesis of normally distributed 
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data, we again selected the direct parametric procedure; if not, we verified the data for 
normality after log-transformation. If the A-D P-value was then 0.05, we applied the 
parametric procedure. Finally, one dataset remained, which was submitted to the non-
parametric bootstrap (500 replicates) procedure, to generate bootstrap estimates of the 
(2.5/100)N+0.5 and (97.5/100)N+0.5 ordered values (22). To test the hypothesis that after 
recalibration a common RI could be used by all manufacturers, we first investigated whether 
the probabilities that the 2.5 and 97.5 percentiles (further also referred to as lower and upper 
limit, respectively), estimated from the datasets of the immunoassays were located within the 
90% CI from the RMP data percentiles (further referred to as reference percentiles), were 
reasonably large (>90%). We repeated the probability testing while using limits of 12.5% 
around the reference percentiles. Probability estimations were done in R 3.2.3 for all assays 
but assay K (Table 1), where the CIs were determined by CB-stat; for the latter, we used the 
R statistical software to perform a bootstrap procedure on the original RI dataset to simulate 
the distribution of the percentiles.  
 
Analytical specifications  
We demonstrated/validated the suitability of the recalibrated results to meet desirable 
specifications for bias and TE based on the biological variation, i.e., 3.3% and 8.0%, 
respectively (23). However, because of the extreme stringency of these values, we also used 
the empirical bias limit of 10% that was considered state-of-the-art in previous MC studies, 
and expanded the TE specification to 13% to account for any imprecision of the RMP (8, 16, 
18, 19). The 12.5% limit used for testing the RI hypothesis was based on the state-of-the-art 
bias specification used above but would additionally account for the uncertainty of the 
location of the reference percentiles.  
 
Homogeneity and stability study  
We assessed the homogeneity and stability of the FT4 standardization panel in the same 
way as described for TSH (11).
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Results  
Concentration range covered by the panels of clinical samples  
The FT4 standardization panel covered a concentration range from 4.5 pmol/L to 164 pmol/L 
(determined by the RMP). The expanded uncertainty of the targets (coverage factor k = 2) 
was estimated to be on the order of 7.0% (16). The central 95% of the RI panel covered the 
range from 13.5 pmol/L (0.7 pmol/L; 90% CI) to 24.3 pmol/L (0.7 pmol/L) with the mean at 
18.9 pmol/L. 
 
Validation of the efficiency of recalibration  
The combined difference plots (Fig. 1) reflect the assays’ calibration biases to the RMP 
before (Fig. 1A) and after recalibration (Fig. 1B). The effect of recalibration on the assay-
specific median deviations (%) to the RMP targets in 4 concentration intervals is shown in 
Fig. 2A by a combined picture with indication of the 15th, 50th and 85th centiles, and in Fig. 2B 
by the individual deviations (more details in Supplemental Table 1). Before recalibration, 
deviations were negative across the FT4 measurement range for all but assay N (<10 
pmol/L). Moreover, the deviations increased with increasing concentration. The highest 
median manufacturer deviations were -40.8% (assay J) (<10 pmol/L), -37.9% (assay F) (≥10 
and <25 pmol/L), -57.7% (assay B) (≥25 and <100 pmol/L), and -72.7% (assay B) (≥100 
pmol/L). The lowest median manufacturer deviations were 7.4% (assay N), -13.7% (assay 
N), -25.6% (assay O) and -30.2% (assay G), respectively. Hence, the most discrepant assay 
pairs (assays J/N, F/N, B/O and B/G) deviated by 48.2%, 24.2%, 32.1% and 42.5%, 
respectively. After recalibration the ranges of the median deviations became -12.0% (assay 
O) to +8.2% (assay A) (<10 pmol/L), -8.9% (assay O) to +1.7% (assay H) (≥10 and <25 
pmol/L), -8.4% (assay H) to +9.5% (assay F) (≥25 and <100 pmol/L), and -12.5% (assay O) 
to +11.9% (assay G) (≥ 100 pmol/L), respectively. Fig. 3 shows the post-recalibration 
differences (%) and the assay biases (%) reflected against the used specifications. From the 
numbers in Supplemental Table 2, we can confidently assert that after recalibration the bias 
12 
 
(and one-sided 95% CI) of all assays but assay O complied with the empirical specification of 
10% at a 95% probability; the bias of 7 assays (A, B, D, E, I, J and N) complied when 
assessed against the 3.3% specification (Supplemental Table 2) (24). With regard to the 
assays’ TE after recalibration, only assay I met the expanded specification, i.e., had 95% of 
its differences within 13%, while for the other assays 8% to 35% of the differences violated it 
(Supplemental Fig. 1). The median differences between the replicates from 2 runs ranged 
from -1.5% (assay K) to 4.1% (assay F), and the SDdiff from 2.5% (assay H) to 5.9% (assay 
A) (Supplemental Table 3). Supplemental Fig. 2 shows that for several assays the 
differences (%) between replicates were concentration-dependent. After recalibration, the CV 
of the assay means (the latter calculated for each assay from all results) decreased from 
13% to 5%. 
 
Reference interval study  
The RI characteristics from the ED-ID-LC-MS/MS measurements were obtained with the 
direct parametric procedure. This procedure was also used for the other normally distributed 
datasets, which excluded the assays A, G, H and K. In spite of a negative outlier test in 
CBstat for these 4 datasets, visual inspection of the plots of assays G and H (Supplemental 
Fig. 3) revealed aberrant differences (%) to the RMP targets (4 for assay G and 3 for assay 
H, respectively). After omission of these aberrant data, the A-D P-values became >0.26 and 
>0.25, respectively, which justified application of the direct parametric procedure to these 
assays. For the assay A, the hypothesis of normality was accepted after log-transformation 
of the data, again justifying the use of the parametric procedure; only for assay K did we 
have to use a non-parametric bootstrap procedure. Supplemental Table 4 lists the main 
characteristics of the respective RIs. The widths of the RIs by the immunoassays ranged 
from 9.4 pmol/L to 12.0 pmol/L versus 10.7 pmol/L for the RMP. The CIs for the respective 
percentiles ranged from 1.1 pmol/L and 2.4 pmol/L (at the 2.5 percentile) and 1.2 pmol/L to 
2.4 pmol/L (at the 97.5 percentile) versus 1.4 pmol/L (for both percentiles of the RMP). The 
range of the means/medians of the RIs was from 17.2/17.0 pmol/L to 20.8/20.5 pmol/L 
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versus 18.9/18.8 pmol/L for the RMP. Supplemental Tables 5 and 6, plus Supplemental 
Figs.. 4 and 5, demonstrate that none of the calculated probabilities for the assays met the 
minimum requirement of >90%. However, after expanding the reference percentile intervals 
to 12.5%, they did for assays E, F, G, H, I, J, L and N at the 2.5 percentile. For the 97.5 
percentile, the >90% requirement was achieved by all but assay A. The graphical overview of 
the respective RIs (Fig. 4) shows that assays A and B had the most discrepant 2.5 
percentiles (calculated to the mean of both percentile values, they were 28% apart), while 
this was the case for assays A and F for the 97.5 percentiles (21% apart).  
 
Homogeneity study  
Statistical testing confirmed that the hypothesis of homogeneity of the aliquots in the 
standardization panel (P>0.05, Supplemental Table 7) could be accepted. The stability study 
is still ongoing.
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Discussion  
The approach to the standardization of commercial FT4 immunoassays was similar to that 
previously described for TSH (11). The Phase I MC demonstrated that mathematical 
recalibration of measurement results for samples from presumably healthy volunteers was 
able to align the different immunoassays to the RMP. The Phase II and III MCs extended the 
findings for euthyroid individuals to patients with hypo- and hyperthyroidism, and provided 
proof-of-concept that manufacturers were also able to do the recalibration by adjusting their 
calibrators (8, 17-19). The current Phase IV MC was the natural next step in our 
standardization project, and the RI study was intended to assess whether recalibration would 
allow a uniform basis for the use of common RIs. The strengths of the FT4 standardization 
approach were the involvement during several years of the globally operating IVD industry 
and the use of a panel of commutable samples, collected to mimic clinical conditions. The 
concentrations of the samples spanned the measurement range of current assays, because 
they were sourced from euthyroid individuals and also from patients with overt 
hypothyroidism and hyperthyroidism.  
The current study confirmed that establishing calibration traceability to the RMP 
significantly reduced the negative biases of the immunoassays, as well as the CV of the 
assay means. However, it is also important to appreciate the huge impact that 
standardization could have on future measurement results and reference intervals. After 
recalibration, 12 of 13 immunoassays had their bias (and CI) meet the empirical specification 
of 10% at a 95% probability, while 7 of them even passed the very stringent specification of 
3.3% derived from the biological variation. Although this outcome is overall reasonable, it 
also points to the fact that the recalibration effectiveness was better for some assays than for 
others.  
The fact that the standardization panel comprised sufficient native samples enabled 
us also to focus on the validation of the post-recalibration TE. This is a very important 
performance attribute because it reflects the accuracy of an assay for measurement of the 
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individual sample. Most assays violated the expanded TE limits in spite of reasonable 
recalibration. This might be due to the specification being too stringent, even after expansion. 
However, considering that in the previous MC studies we already highlighted the TE issue of 
many FT4 immunoassays due to their susceptibility to sample-related effects, it is more 
realistic to suggest that our current study confirms this limitation.  
Finally, the results on the differences between replicates highlight the occasional high 
inter-run imprecision and lack of robustness of calibration (Supplemental Table 3, 
Supplemental Fig. 2). The importance of continual improvement of these performance 
attributes across all assays was discussed with the IVD manufacturers. 
The aim of the current RI study was primarily to supply a proof-of-concept that after 
recalibration the use of a common RI may be feasible. We used the RI estimated from the 
measurement data by ED-ID-LC-MS/MS as reference and assessed whether the recalibrated 
assays could share it. We inferred the percentiles and mean of the central 95% of all but one 
RI by a parametric procedure applied to either the original or log-transformed data. 
Interestingly, the width of the interval by the RMP corresponded reasonably with that 
calculated from the FT4 biological variation, i.e., 10.7 pmol/L versus 9.6 pmol/L, as well as 
that estimated in another study using ED-ID-LC-MS/MS, i.e., 12.1 pmol/L (23, 25). However, 
it was most important to compare the derived immunoassay percentiles of the RIs with those 
of the RMP. In the employed statistical approach an immunoassay would be qualified to 
share the RI of the RMP if the probability that its percentiles were located within the CI 
around the reference was higher than 90%. None of the assays met this criterion. However, 
when an interval of ±12.5% was adopted, the probabilities of eight assays met the >90% 
requirement at the 2.5 percentiles, and of all but one assay also at the 97.5 percentiles. We 
present 3 reasons to justify the hypothesis of testing with the 12.5% margin around the 
reference percentiles. First is the observation that the magnitudes of the CIs around the 
reference percentiles were 5%, thus similar to or narrower than the assays’ effective biases 
in the euthyroid range after recalibration (range 0% up to 9%). Second, we refer to the 
impact of the lot-to-lot variation on the RI study, which was performed with a time offset of at 
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least 6 months compared to the Phase IV MC. Third, we found it legitimate to account to a 
certain extent for the uncertainty of the location of the estimated reference percentiles due to 
the potential impact of an undetectable bias in the measurements with the RMP. 
Nevertheless, even if the current margin of 12.5% accommodates the current state-of-the-art 
measurements, we advocate that in the future it should be decreased, particularly because of 
the low biological variation of serum FT4. We also recommended the IVD manufacturers of 
the assays that did not accord with the RMP to share its percentiles, in spite of adopting the 
12.5% margin, to do root cause analysis. 
In conclusion, the Phase IV MC study described here showed that, in general, the 
recalibration process was able to eliminate the considerable FT4 calibration biases to the 
RMP. In addition, the basic RI study provided the proof-of-concept since the percentiles of 
the RMP applied for most of the recalibrated assays within a margin of 12.5%. Although this 
result represents substantial progress in standardization of FT4 measurements, we 
recognize that it cannot be extrapolated to all clinical situations where FT4 testing is 
indicated, particularly when binding proteins are abnormal. Therefore, to better understand 
more-subtle assay differences in other patient cohorts such as pregnant females and 
patients with the non-thyroidal illness syndrome, we recommend that our approach serve as 
model for future studies. We also see surveillance of the sustainability of the recalibration 
basis as a final key component of our standardization approach. We propose that, after 
implementation of the recalibrated assays, the surveillance should be done under field 
conditions to account for the impact of variables like lot-to-lot changes and instrument 
instability. This could be done by using the Percentiler/Flagger applications described 
elsewhere as useful tools for continuous monitoring of the stability of performance/flagging 
frequency in laboratories grouped according to instrument/assay-specific peers (26). Another 
tool could be the organization of proficiency testing or external quality assessment surveys 
with commutable samples (27). We also recognize that we should expand the measurement 
capacity with the conventional RMP. Therefore, we are currently working on establishing a 
network of competent reference laboratories. Last but not least, from the perspective that 
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implementing the recalibrated FT4 assays will have a huge impact on future measurement 
results and RIs, we are committed to gaining broad consensus on this step (28).
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Table 1. Study participants (ordered by code), inclusive the platforms/FT4 assays 
examined for standardization. The listed reference and measurement intervals are 
those stated in the kit inserts.  
IVD manufacturer 
Platform/Immunoassay 
Code 
Reference Interval 
(pmol/L) 
Measurement 
Interval 
(pmol/L)c-g 
Siemens Healthineers (Tarrytown, NY); 
Advia Centaur XP 
A 11.5 - 22.7 (n = 388) 1.3c - 155 
Abbott Diagnostics (Abbott Park, IL); 
Architect i2000 
B 9.0 - 19.1 (99%, 
 n = 411) 
5.2d - 77 
Ortho-Clinical Diagnostics 
(Buckinghamshire, UK);  
Vitros ECi 
D 10.0 - 28.2 (98%, 
 n = 535) 
0.9c - 90 
bioMérieux SA (Marcy-l’Etoile, France) ; 
Vidas 
E 10.6 – 19.4 (95%,  
n = 623) 
1.1e - 100 
Beckman Coulter Inc. (Brea, CA); 
Access 2 
F 7.9 – 14.4 (95%, 
n = 316) 
3.2e - 77 
DiaSorin S.p.A (Saluggia, Italy); 
Liaison® Analyser 
G 10.3 - 21.9 (95%,  
n = 517) 
1.3c - 129 
aSichuan Maccura Biotechnology Co., 
Ltd (Chengdu, China); 
IS1200 
H 12.2 - 21.2 (95%,  
n = 175) 
2.0e - 100 
Roche Diagnostics GmbH (Mannheim, 
Germany);  
Elecsys (Cobas e 601) 
I 12.0 – 22.0 (95%,  
n = 801) 
3.0f - 100 
Tosoh Corporation (Tokyo, Japan); 
AIA-2000 
J 10.6 – 21.0 (95%,  
n = 618) 
1.3e - 103 
aSnibe Co.,Ltd, (Shenzhen, China); 
Maglumi 2000 
K 11.5 - 22.1 (95%) 1.3g - 154 
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aFujirebio Inc. (Tokyo, Japan);  
Lumipulse G1200 
L 9.7 - 19.8 (95%,  
n = 141) 
1.0c – 129 
bLSI Medience Corporation (Tokyo, 
Japan); 
STACIA 
N 12.5 - 26.5 1.3e - 103 
bSysmex Corporation (Kobe, Japan);  
HISCL-5000 
O 9.9 - 20.5 3.2e - 77 
a,bManufacturers who only joined in 2015a and/or 2016b for participation in the Phase IV 
method comparison study. 
c-gThe lower limit of the measurement intervals is: climit of detection (according to the CLSI’s 
EP-17 protocol); dfunctional sensitivity (CV 10%); efunctional sensitivity (CV 20%); flimit of 
quantification at a total error of ±30% (CLSI EP-17); glimit of quantificiation (CLSI EP-17) 
(21). 
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Figure Legends 
 
Figure 1. Combined difference (%) plots of the immunoassay results to those by ED-
ID-LC-MS/MS, before (A) and after recalibration (B).  
The most discrepant assays before recalibration are highlighted by colored symbols (blue 
circles for assay B (< 25 pmol/L) and assay F (> 25 pmol/L); red triangles for assay N), while 
all other assays are indicated with the symbol X. The red broken lines are the bias limits 
based on the biological variation concept: ±3.3% (it is to note that we converted the 
percentage limit to 0.165 pmol/L for concentrations 5 pmol/L), while the red dotted lines are 
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the empirical bias limits of 10% (8, 18,19). The blue broken lines represent the 15th and 85th 
centiles. 
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Figure 2. Median deviations (%) of the immunoassays to ED-ID-LC-MS/MS before and 
after recalibration in 4 concentration intervals: <10 pmol/L, 10 – 25 pmol/L, 25 – 100 
pmol/L and >100 pmol/L. 
(A) the overall improvement in terms of the median deviations (%) by recalibration. For each 
concentration interval, 2 pairs of data are shown; the black and red dots show the combined 
assay-specific median deviations before and after recalibration, respectively; the lines 
represent the 15th, 50th and 85th centiles; (B) the median deviations (%) of each assay by a 
pair of bars; the upper and lower bar shows the median deviation before and after 
recalibration, respectively. Note that the bars represent the unsigned magnitudes, while the 
colors refer to the signs (blue: negative, red: positive).  
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Figure 3. Difference (%) plots after recalibration of the individual immunoassays. 
The red dotted lines are the 3.3% bias limits from the biological variation concept (converted 
to 0.165 pmol/L for concentrations 5 pmol/L), while the red broken lines stand for the 
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previously used empirical limits of 10% (8, 18,19). The blue line represents for each 
immunoassay the mean deviation or bias (%). The one-sided 95% CIs given in Supplemental 
Table 2 are not shown because of too little graphical resolution. To keep the Y-axes identical 
in all plots, certain % differences required omission (concentrations and % differences 
mentioned in the plots).  
 
Figure 4. Comparison of the reference interval percentiles of the individual 
immunoassays to those of ED-ID-LC-MS/MS (n = 120).  
The blue thick horizontal bars represent the respective 2.5 percentiles and 97.5 percentiles 
of each reference interval, while the blue vertical lines show the respective 90% CIs. The red 
thick horizontal bars for each assay stand for the mean (except for assay K, for which it 
shows the median). The grey and black broken horizontal lines represent the reference 
percentiles (from the data by the RMP) and the 90% CIs around them, respectively. The red 
dotted lines are the 12.5% limits of the interval around the reference percentiles. 
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1 Assay-specific median deviations (%) (pre- and post-recalibration)  
Table 1: Median deviation (%) of each of the immunoassays to ED-ID-LC-MS/MS before and after recalibration in 4 concentration 
intervals. 
 
Assay  Before recalibration After recalibration 
<10 pmol/L ≥10 <25 pmol/L ≥25 <100 pmol/L ≥100 pmol/L <10 pmol/L ≥10 <25 pmol/L ≥25 <100 pmol/L ≥100 pmol/L 
A -5.9 -24.6 -39.1 -49.0 8.2 -3.6 -2.3 10.0 
B -16.0 -34.2 -57.7 -72.7 6.8 1.0 6.3 -12.4 
D -29.1 -27.4 -29.2 -45.5 0.4 -0.6 4.4 0.3 
E -23.5 -22.3 -31.7 -42.4 -5.8 0.1 2.1 0.5 
F -28.4 -37.9 -45.6 -58.7 6.1 -1.4 9.5 0.0 
G -18.8 -27.2 -35.7 -30.2 -1.2 -1.0 -3.9 11.9 
H -24.5 -32.0 -46.2 -48.9 4.5 1.7 -8.4 -1.1 
I -16.7 -22.5 -32.7 -41.6 -4.5 -0.6 0.2 -2.2 
J -40.8 -32.4 -34.3 -46.1 8.0 -0.2 -1.3 -2.6 
K -13.1 -31.1 -46.2 -58.1 1.1 -6.3 -8.3 -9.1 
L -26.4 -33.7 -40.2 -45.2 -5.4 -5.8 0.6 7.9 
N 7.4 -13.7 -29.1 -42.1 -4.0 -0.6 -1.7 -11.9 
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O -19.5 -20.9 -25.6 -41.7 -12.0 -8.9 -4.9 -12.5 
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2 Post-recalibration biases (%) 
Table 2: Assay biases/mean deviations (%) and one-sided 95% confidence interval (CI) 
after recalibration to the ED-ID-LC-MS/MS targets, and their assessment against 2 
specifications: 3.3% inferred from the biological variation and 10% used as an 
empirical limit.  
Assay  Bias (%) One-sided*  
95% CI (%) 
Upper bias 
limit (%)  
(Bias + CI) 
Lower bias  
limit (%)  
(Bias – CI) 
A -0.1 2.0 1.9 -2.2 
B 1.2 2.0 3.2 -0.8 
D 1.5 1.6 3.1 -0.1 
E -0.5 2.0 1.6 -2.5 
F 2.5 1.8 4.3 0.7 
G 1.7 2.0 3.7 -0.4 
H 4.1 4.0 8.1 0.1 
I -0.2 1.2 1.0 -1.4 
J 0.9 1.3 2.2 -0.5 
K -4.6 2.5 -2.2 -7.1 
L -1.3 2.2 0.9 -3.6 
N -1.3 1.6 0.3 -2.9 
O -9.2 1.3 -7.9 -10.5 
*One-sided t-values (obtained from Excel with the function TINV(0.1, df)) were used for the 
calculation of the CI. 
Interpretation: it can be confidently asserted that after recalibration the bias (and 95% CI) of 
all but assay O met the empirical specification of 10% with at 95% probability; for assay O (in 
spite of a bias below 10%) this statement does not apply as the lower 95% CI limit violated 
the specification (purple cell). When validating the biases against the 3.3% specification, 
those of 3 out of 13 assays (H, K, and obviously O; biases underlined) violated it; in addition, 
for 3 other assays (F, G and L), in spite of having biases less than ±3.3%, it is not possible to 
state with 95% confidence that the specification was complied with (one of the 95% CI limits 
(orange cells) was outside either + or -3.3%) (Ref. 23 in the main text).  
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3 Total error plots after recalibration 
Figure 1: FT4 total error (TE) plots. The TE at the level of the individual sample was 
estimated from the % difference to the RMP target of the first replicate after recalibration. For 
validation, we used the TE specification from the biological variation concept (red broken 
lines), but expanded it from 8.0% to 13% to account for the imprecision of the ED-ID-LC-
MS/MS RMP. We also added the 95% limits of agreement (mean % difference  1.96 CVdiff 
(%); blue broken lines) to emphasize on the fact that the magnitude of the scatter in the plots 
is different from assay to assay. 
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Figure 1: FT4 TE plots, continued.  
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3 Differences (%) between the replicates 
Table 3: Median differences (%) between the replicates from 2 runs (relative to the 
mean) and SDdiff (%). Note that the calculations were done from the reported results 
before recalibration. 
Assay 
Median 
difference 
(%) 
SDdiff (%) 
A 3.1 5.9 
B -0.4 4.1 
D -1.1 5.6 
E 0.2 3.6 
F 4.1 5.6 
G 0.6 3.9 
H 1.4 2.5 
I 3.1 2.7 
J 1.0 5.0 
K -1.5 3.5 
L 0.9 4.4 
N 2.4 4.5 
O -1.3 2.7 
 
39 
 
 
Figure 2: Difference (%) plots between the replicates obtained from different runs. Note that 
the samples for which the deviation was beyond 25% were not included in the plots; they are 
identified in the respective graphs by their concentration (according to ED-ID-LC-MS/MS) 
and difference (%).  
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Figure 2: Difference (%) plots between the replicates, continued. 
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4 Reference interval study – Additional figures and tables 
 
Figure 3: Difference (%) plots of the results by the immunoassays for the reference interval 
study against those by ED-ID-LC-MS/MS. The red broken line represents the expanded TE 
limit (13% for n = 1). The red circles in the plots of assays G and H identify the differences 
(%) we visually identified as aberrant in comparison to the bulk of the data. As described in 
the main text, after removal of these data, the A-D test gave P>0.05, which allowed use of 
the direct parametric procedure for estimating the RI characteristics of these 2 assays.  
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Figure 3: Difference (%) plots for the reference interval study (continued). 
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Table 4: Characteristics of the different reference intervals.  
 
ID 
Mean/Median 
concentration  
Width 
RI 
2.5 
centile 
90% CI 
97.5 
centile 
90% CI 
52.5 
cent. 
597.5 
cent. 
 (pmol/L) (%) 
RMP 18.9/18.8 10.7 13.5 12.8 - 14.2 24.3 23.6 - 25.0   
A1 20.8/20.54 11.8 15.5 15.0 - 16.1 27.3 26.3 - 28.3 14.96 12.66 
B 17.7/17.8 12.0 11.7 11.0 - 12.5 23.7 22.9 - 24.5 
-
13.26 
-2.3 
D 18.0/17.7 12.0 12.0 11.2 - 12.8 24.0 23.3 - 24.8 -11.1 -0.9 
E 18.2/18.5 11.5 12.5 11.7 - 13.2 23.9 23.2 - 24.7 -7.7 -1.3 
F 17.3/17.1 9.6 12.5 11.9 - 13.1 22.1 21.4 - 22.7 -7.8 -9.1 
G2 17.7/17.5 10.0 12.7 12.0 - 13.3 22.7 22.0 - 23.3 -6.1 -6.5 
H2 20.2/19.8 11.6 14.4 13.6 - 15.2 26.0 25.2 - 26.8 6.5 7.1 
I 18.7/18.6 10.7 13.4 12.7 - 14.1 24.0 23.3 - 24.7 -1.2 -0.9 
J 18.9/18.7 10.1 13.8 13.2 - 14.5 24.0 23.3 - 24.6 2.4 -1.3 
K3 17.7/17.1 11.2 12.4 11.3 - 13.8 23.6 22.4 - 24.8 -8.6 -2.7 
L 17.8/17.6 10.4 12.6 11.9 - 13.3 23.0 22.3 - 23.7 -6.7 -5.2 
N 18.7/18.4 9.4 14.0 13.3 - 14.6 23.4 22.8 - 24.0 3.4 -3.7 
O 17.2/17.0 10.4 12.0 11.3 - 12.7 22.4 21.7 - 23.1 -11.5 -7.6 
1Parametric after log-transformation.  
2Parametric after removal of visually observed aberrant % differences to the target outliers 
(see above Figure 4S). 
3Non-parametric bootstrap. Note, the increased width of the CI for assay K compared to the 
other assays is related to the statistical procedure (non-parametric bootstrap) used to 
estimate the RI. 
4Geometric mean because the distribution of the dataset was not normal. 
5Difference (%) to the reference 2.5 and 97.5 percentile, respectively. 
6Difference (%) to the reference percentile(s) exceeding the 12.5% limit. 
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5 Statistical testing of the hypothesis that the percentiles of the 
reference interval by the RMP suits for common use  
 
Table 5: Calculation of the probability that the 2.5- and 97.5-percentiles of the 
immunoassays are located in the interval flanked by the CI limits of the reference 
percentiles. 
Assay Probability 2.5-percentile (%) Probability 97.5-percentile (%) 
A 0.0 0.0 
B 1.1 61 
D 4.7 81 
E 23 78 
F 18 0.0 
G 38 1.4 
H 36 1.7 
I 88 85 
J 82 83 
K 20 25 
L 31 9.1 
N 74 31 
O 2.1 0.3 
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Figure 4: Visualization of the statistical test that calculates the probability that the 2.5- and 
97.5-percentiles of the immunoassays are located in the interval flanked by the CI limits of 
the reference percentiles (indicated by the blue and red shaded zones). The blue and red 
vertical lines/horizontal bars represent the 90% CI of the RMP and the 13 assays for the 2.5- 
and 97.5-percentiles, respectively. 
 
 
Re
fe
re
nc
e 
In
te
rv
al 
(p
m
ol
/L
) 
48 
 
 
Table 6: Calculation of the probability that the 2.5- and 97.5-percentiles of the 
immunoassays are located in the 12.5% interval around the reference percentiles. 
Assay Probability 2.5-percentile (%) Probability 97.5-percentile (%) 
A 16 49 
B 42 100 
D 65 100 
E 92 100 
F 95 99 
G 99 100 
H 95 100 
I 100 100 
J 100 100 
K 86 100 
L 97 100 
N 100 100 
O 63 100 
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Figure 5: Visualization of the statistical test that calculates the probability that the 2.5- and 
97.5-percentiles of the immunoassays are located in the 12.5% interval around the reference 
percentiles (indicated by the blue and red shaded zones). The blue and red vertical 
lines/horizontal bars represent the 12.5% interval around the reference percentiles, and the 
90% CI of the 13 assays for the 2.5- and 97.5-percentiles, respectively.  
Re
fe
re
nc
e 
In
te
rv
al 
(p
m
ol
/L
) 
50 
 
 
6 Summary of the results of the homogeneity study 
 
Table 7: Summary of the results of the homogeneity study. 
Sample ID Mean (pmol/L) 
(aliquots) 
CV (%) 
(aliquots) 
Mean (pmol/L) 
(pool) 
CV (%) 
(pool) 
P (F-test, 95% CLa) 
1 18.5 0.7 18.5 1.1 0.2 
2 17.9 0.6 18.0 0.2 0.5 
3 7.7 0.7 7.7 1.0 0.3 
4 9.0 0.3 9.1 0.8 0.5 
5 31.3 0.6 31.3 0.8 0.4 
6 83.4 1.3 83.0b 1.0 0.5 
7 11.1 0.6 11.1 0.8 0.5 
8 28.2 0.6 28.3 1.0 0.2 
9 17.9 0.7 17.8 1.0 0.4 
10 14.1 0.6 14.1 0.5 0.6 
11 18.0 0.5 18.0 0.7 0.7 
12 9.0 0.8 9.0 0.6 0.5 
aCL: confidence level 
b: 1 Outlier identified with the Grubbs test 
 
 
